BRIEF published on 04/04/2025 at 14:05, 8 months 1 day ago Oxurion General Meeting Postponed General Meeting Biopharmaceuticals Report Ophthalmic Therapies Oxurion
PRESS RELEASE published on 04/04/2025 at 14:00, 8 months 1 day ago Postponement Annual Shareholders Meeting Oxurion NV postponed its Annual Shareholders Meeting to May 13, 2025, due to pending annual accounts. The biopharmaceutical company, focused on ophthalmic therapies, is based in Leuven, Belgium Biopharmaceutical Annual Shareholders Meeting Postponed Ophthalmic Therapies Oxurion NV
BRIEF published on 04/02/2025 at 18:05, 8 months 2 days ago Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC Actions Transparency Atlas Special Opportunities Oxurion Biopharmacy
PRESS RELEASE published on 04/02/2025 at 18:00, 8 months 2 days ago Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC Oxurion NV, a biopharmaceutical company, received a transparency notification from Atlas Special Opportunities II, LLC regarding shareholding threshold crossing under Belgian legislation Transparency Notification Shareholding Threshold Oxurion NV Belgian Legislation Atlas Special Opportunities II LLC
BRIEF published on 03/27/2025 at 18:05, 8 months 8 days ago Oxurion receives adjusted transparency notification Transparency Notification Shareholding Oxurion Atlas Special Opportunities II Brussels Stock Exchange
PRESS RELEASE published on 03/27/2025 at 18:00, 8 months 8 days ago Oxurion Receives Amended Transparency Notification from Atlas Special Opportunities II LLC Oxurion NV received an amended transparency notification from Atlas Special Opportunities II, LLC regarding the sale of voting securities. This press release replaces the one from March 18, 2025 Transparency Notification Euronext Brussels Oxurion NV Retinal Disease Therapies Atlas Special Opportunities II
BRIEF published on 03/24/2025 at 18:05, 8 months 11 days ago Oxurion Announces Capital Increase Following Convertible Bond Conversion Convertible Bonds Capital Increase Atlas Special Opportunities Ophthalmic Therapies Oxurion
PRESS RELEASE published on 03/24/2025 at 18:00, 8 months 11 days ago Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Atlas Special Opportunities, LLC converts bonds in Oxurion, resulting in EUR 150,000 capital increase. Oxurion focuses on developing therapeutics for vision care Capital Increase Therapeutics Vision Care Atlas Special Opportunities LLC Oxurion
BRIEF published on 03/18/2025 at 18:35, 8 months 17 days ago Oxurion Signs Letter of Intent for Acquisition of Biometrics-Focused CRO Regulatory Compliance Oxurion Acquisition Biometrics CRO Clinical Data Management ECRF Platform
PRESS RELEASE published on 03/18/2025 at 18:30, 8 months 17 days ago Oxurion signs a letter of intent for the planned acquisition of a biometrics-focused CRO Oxurion NV plans to acquire majority stake in a specialized CRO for clinical data management. Strategic move aligns with company's expansion strategy. Transaction valued at €650,000 Acquisition CRO Biometric Analysis Oxurion NV Clinical Data Management
Published on 12/05/2025 at 16:00, 33 minutes ago SMX Didn't Change Its Story; The World Finally Connected the Dots
Published on 12/05/2025 at 15:45, 48 minutes ago Critical Elements Announces Closing of C$7.0 Million Bought Deal Life Private Placement
Published on 12/05/2025 at 15:35, 58 minutes ago XCF Global Moves to Double SAF Production with New Rise Reno Expansion
Published on 12/05/2025 at 15:00, 1 hour 33 minutes ago Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Published on 12/05/2025 at 16:25, 8 minutes ago 4YFN26 Awards: Meet the Top 20 startups building the future
Published on 12/05/2025 at 16:10, 23 minutes ago Reorganization of the Eckert & Ziegler Executive Board
Published on 12/05/2025 at 16:00, 33 minutes ago EQS-Adhoc: TIN INN Holding AG implements financing strategy
Published on 12/05/2025 at 16:00, 33 minutes ago EQS-Adhoc: Amundi Physical Metals plc: Release of the Half-Year Financial Report as of September 30, 2025
Published on 12/05/2025 at 16:00, 33 minutes ago Amundi Physical Metals plc: Release of the Half-Year Financial Report as of September 30, 2025
Published on 12/05/2025 at 15:10, 1 hour 22 minutes ago Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 08:45, 7 hours 48 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 22 hours 33 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 22 hours 48 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 22 hours 49 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
